JP2018516230A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516230A5 JP2018516230A5 JP2017549330A JP2017549330A JP2018516230A5 JP 2018516230 A5 JP2018516230 A5 JP 2018516230A5 JP 2017549330 A JP2017549330 A JP 2017549330A JP 2017549330 A JP2017549330 A JP 2017549330A JP 2018516230 A5 JP2018516230 A5 JP 2018516230A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- derivative
- kcnk9
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004965 antibodies Human genes 0.000 claims 24
- 108090001123 antibodies Proteins 0.000 claims 24
- 102100005810 KCNK9 Human genes 0.000 claims 6
- 101700009873 KCNK9 Proteins 0.000 claims 6
- 210000004027 cells Anatomy 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 102000004257 potassium channel family Human genes 0.000 claims 3
- 108020001213 potassium channel family Proteins 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027476 Metastasis Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000012202 endocytosis Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000004083 survival Effects 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Claims (15)
- KCNK9カリウムチャネルの細胞外ドメインの少なくとも1つのエピトープに特異的に結合する単離された抗体、抗体断片、またはそれらの誘導体。
- 前記抗体、断片、またはそれらの誘導体が他のカリウムチャネルに結合しない、請求項１に記載の抗体、断片、または誘導体。
- 少なくとも1つの前記エピトープがM1P1ドメインを含む、請求項１または２に記載の抗体、断片、または誘導体。
- 少なくとも1つの前記エピトープが、配列番号1のアミノ酸Glu30とIle88との間にエピトープを含む、請求項１〜３のいずれか一項に記載の抗体、断片、または誘導体。
- 前記抗体、断片、または誘導体がKCNK9活性を阻害する、請求項１〜４のいずれか一項に記載の抗体、抗体断片、または誘導体。
- 細胞表面上の少なくとも1つの前記エピトープへの抗体、断片、または誘導体の結合が、前記細胞表面上のカリウムチャネルの内在化およびエンドサイトーシスを引き起こす、請求項１〜５のいずれか一項に記載の抗体、断片、または誘導体。
- KCNK9発現細胞の表面上の少なくとも1つの前記エピトープへの抗体、断片、または誘導体の結合が、前記KCNK9発現細胞の生存を阻害する、請求項１〜６のいずれか一項に記載の抗体、断片、または誘導体。
- 前記抗体がY4である、請求項１〜７のいずれか一項に記載の抗体、断片、または誘導体。
- 前記抗体、断片、または誘導体が少なくとも1つの薬剤に結合しており、
前記薬剤が、治療薬剤、標識薬剤、および抗新生物剤からなる群より選択される、請求項１〜８のいずれか一項に記載の抗体、断片、または誘導体。 - 前記抗体、断片、または誘導体がリンカーを介して少なくとも1つの前記薬剤に結合しており、
前記リンカーが、切断可能なリンカーおよび切断不能なリンカーからなる群より選択される、請求項９に記載の抗体、断片、または誘導体。 - 請求項１〜１０のいずれか一項に記載の抗体、断片、または誘導体を含み、
少なくとも1つの抗新生物剤をさらに含む医薬組成物。 - 請求項１〜１０のいずれか一項に記載の抗体、断片、または誘導体を含む診断用組成物。
- 請求項１〜１０のいずれか一項に記載の抗体、断片または誘導体を含むキット。
- KCNK9発現細胞の存在を評価する方法であって、KCNK9をその表面上に発現することが疑われる細胞または組織を、請求項１〜１０のいずれか一項に記載の抗体、断片、もしくは誘導体、または請求項１２に記載の診断用組成物とin vitroで接触させることを含む方法。
- がんを有するかまたは有すると疑われる被験体における腫瘍の増殖および／または転移の阻害用であって、
前記がんが、乳がんおよび肺がんからなる群より選択される、請求項１〜１０のいずれか一項に記載の抗体、断片、もしくは誘導体。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562134724P | 2015-03-18 | 2015-03-18 | |
| US62/134,724 | 2015-03-18 | ||
| US201562186772P | 2015-06-30 | 2015-06-30 | |
| US62/186,772 | 2015-06-30 | ||
| PCT/US2016/023144 WO2016149621A1 (en) | 2015-03-18 | 2016-03-18 | Novel monoclonal antibody inhibitors targeting potassium channel kcnk9 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018516230A JP2018516230A (ja) | 2018-06-21 |
| JP2018516230A5 true JP2018516230A5 (ja) | 2019-03-14 |
Family
ID=56920355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017549330A Pending JP2018516230A (ja) | 2015-03-18 | 2016-03-18 | カリウムチャネルｋｃｎｋ９を標的とする新規モノクローナル抗体阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20180092977A1 (ja) |
| EP (1) | EP3271397B1 (ja) |
| JP (1) | JP2018516230A (ja) |
| KR (1) | KR20180026659A (ja) |
| CN (1) | CN108368169A (ja) |
| AU (1) | AU2016232749B2 (ja) |
| WO (1) | WO2016149621A1 (ja) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021247805A1 (en) * | 2020-06-05 | 2021-12-09 | The Johns Hopkins University | Humanized antibodies directed against kcnk9 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| EP0362371A4 (en) | 1988-04-15 | 1990-10-24 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| ATE160379T1 (de) | 1990-10-29 | 1997-12-15 | Chiron Corp | Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| PT804070E (pt) | 1993-03-09 | 2000-11-30 | Genzyme Corp | Isolamento de componentes de interesse a partir do leite. |
| AU7518194A (en) | 1993-07-29 | 1995-02-28 | Regents Of The University Of California, The | Polynucleotide decoys that ihnibit mhc-ii expression and uses thereof |
| UA40577C2 (uk) | 1993-08-02 | 2001-08-15 | Мерк Патент Гмбх | Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
| ATE469242T1 (de) | 2000-03-27 | 2010-06-15 | Univ Jefferson | Zusammensetzungen und methoden zur identifizierung und zum targeting von krebszellen aus dem verdauungskanal |
| WO2002098897A2 (en) * | 2001-06-01 | 2002-12-12 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| US7786279B2 (en) * | 2003-02-27 | 2010-08-31 | Yeda Research And Development Co. Ltd. | Nucleic acid molecules, polypeptides, antibodies and compositions for treating and detecting influenza virus infection |
| WO2005075510A1 (en) | 2004-02-04 | 2005-08-18 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with potassium channel, subfamily k, member 9 (kcnk9) |
| EP2012758A2 (en) * | 2006-04-27 | 2009-01-14 | Sanofi-Aventis Deutschland GmbH | Inhibitors of the task-1 and task-3 ion channel |
| KR101213796B1 (ko) | 2010-10-28 | 2012-12-18 | 경상대학교산학협력단 | Ｔａｓｋ-３ 칼륨 채널의 발현증가에 의한 암전이 억제 |
-
2016
- 2016-03-18 EP EP16765829.3A patent/EP3271397B1/en active Active
- 2016-03-18 CN CN201680026543.8A patent/CN108368169A/zh active Pending
- 2016-03-18 AU AU2016232749A patent/AU2016232749B2/en active Active
- 2016-03-18 WO PCT/US2016/023144 patent/WO2016149621A1/en active Application Filing
- 2016-03-18 JP JP2017549330A patent/JP2018516230A/ja active Pending
- 2016-03-18 US US15/559,220 patent/US20180092977A1/en not_active Abandoned
- 2016-03-18 KR KR1020177029927A patent/KR20180026659A/ko unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001580A1 (es) | Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped. | |
| AR078470A1 (es) | Anticuerpos que se unen especificamente al receptor epha2 | |
| ECSP099074A (es) | Anticuerpo antagonista para el tratamiento del cáncer | |
| WO2010005566A3 (en) | Notch-binding agents and antagonists and methods of use thereof | |
| NZ750426A (en) | Modified t lymphocytes having improved specificity | |
| EA032908B1 (ru) | Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7 | |
| WO2010065954A3 (en) | Sparc binding peptides and uses thereof | |
| WO2008045976A3 (en) | Compositions and methods for treating and diagnosing cancers | |
| MX2014000054A (es) | Moleculas de union anti-alfa sinucleina. | |
| WO2006079120A3 (en) | Fc-fusion constructs binding to phosphatidylserine and their therapeutic use | |
| MX338754B (es) | Anticuerpos humanos contra el factor tisular. | |
| NZ606195A (en) | Methods and compositions for liver cancer therapy | |
| WO2006099141A3 (en) | Anti-mesothelin antibodies | |
| JP2009256388A5 (ja) | ||
| WO2009142738A3 (en) | Compositions and methods for diagnosing and treating cancer | |
| UY29029A1 (es) | Uso de tinturas de cianina para el diagnóstico de enfermedades asociadas con angiogénesis | |
| CA2740134C (en) | Formulations targeting igfbp7 for diagnosis and therapy of cancer | |
| CO6612264A2 (es) | Proteinas terapeuticas de la union a dll 4 | |
| WO2006116592A3 (en) | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells | |
| CY1115212T1 (el) | Διαμεσολαβηση στην κυτταροτοξικοτητα των κυτταρων που παρουσιαζουν eπιφaneiakh εκφραση της cd44 | |
| CR10143A (es) | Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer | |
| JP2014223083A5 (ja) | ||
| WO2008003656A3 (en) | Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics | |
| BR112014029089A2 (pt) | anticorpo ou um fragmento de ligação de antígeno do mesmo; polinucleótido codificador; composto; composição/formulação farmacêutica; kit; uso; método in vitro para reduzir ou inibir a atividade da enzima tg2 | |
| WO2010099139A3 (en) | Combination of an either an anti-igf-ir- antibody or an igf binding protein and a small molecule igf-ir kinease inhibitor |